Literature DB >> 19343496

The additional loss of Bak and not the lack of the protein tyrosine kinase p56/Lck in one JCaM1.6 subclone caused pronounced apoptosis resistance in response to stimuli of the intrinsic pathway.

J Rudner1, A-C Mueller, N Matzner, S M Huber, R Handrick, C Belka, V Jendrossek.   

Abstract

Ionising radiation, hypoxia, and the cyclooxygenase-2 inhibitor Celecoxib are known agonists of the intrinsic apoptosis pathway that involves mitochondrial damage upstream of caspase activation. Mitochondrial integrity is regulated by the pro-apoptotic Bcl-2 protein family members Bak and Bax. Upstream of the mitochondria, many kinases and phosphatases control the apoptotic response. However, the role of the non-receptor tyrosine kinase p56/Lck during apoptosis is controversial. The present investigation demonstrate the existence of two JCaM1.6 subclones, one expressing and one deficient for Bak. The lack of p56/Lck expression in JCaM1.6 cells per se did hardly affect apoptosis induced by ionising radiation, hypoxia, or Celecoxib. Only the additional loss of Bak expression, as observed in one JCaM1.6 subclone, rendered the cells resistant. siRNA-mediated downregulation of Bak and p56/Lck mimicked the observed effects in the subclones. Earlier experiments performed with the Bak-negative clone might have lead to the wrong assumption that lack of p56/Lck alone, and not the additonal loss of Bak, was responsible for reduced sensitivity towards stimuli of the intrinsic apoptosis pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19343496     DOI: 10.1007/s10495-009-0342-x

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  3 in total

Review 1.  Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

Authors:  Leyte L Winfield; Florastina Payton-Stewart
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

2.  Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.

Authors:  B Elsberger; R Fullerton; S Zino; F Jordan; T J Mitchell; V G Brunton; E A Mallon; P G Shiels; J Edwards
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

3.  Dihydroartemisinin is a Hypoxia-Active Anti-Cancer Drug in Colorectal Carcinoma Cells.

Authors:  Teona Ontikatze; Justine Rudner; René Handrick; Claus Belka; Verena Jendrossek
Journal:  Front Oncol       Date:  2014-05-19       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.